Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
Sophie BéliardSamir SahebStéphanie Litzler-RenaultAlexandre VimontRené ValéroÉric BruckertMichel FarnierAntonio GalloPublished in: Arteriosclerosis, thrombosis, and vascular biology (2024)
Real-life, long-term evinacumab adjunctive to lipid-lowering therapy including lipoprotein apheresis led to sustained low-density lipoprotein cholesterol lowering and improved cardiovascular event-free survival of patients with HoFH.